Related Experiment Video
Updated: Oct 29, 2025
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
43.3K
Aducanumab: The first targeted Alzheimer's therapy
1Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Drug Discoveries & Therapeutics
|July 8, 2021
Summary
Alzheimer's disease (AD) is a progressive dementia. Aducanumab, a new antibody therapy, targets amyloid plaques and offers hope, though its approval is debated.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) is an irreversible dementia characterized by amyloid plaques.
- AD mortality has increased while stroke and heart disease mortality decreased.
- Current AD treatments only manage symptoms, not disease progression.
Purpose of the Study:
- To evaluate aducanumab, a novel monoclonal antibody for Alzheimer's disease.
- To assess aducanumab's efficacy in reducing amyloid plaques and slowing AD progression.
Main Methods:
- Aducanumab, a human monoclonal antibody, targets aggregated amyloid-beta.
- The therapy aims to reduce amyloid plaque deposits in the brain.
Main Results:
- Aducanumab preferentially binds to aggregated amyloid-beta.
- The drug was approved as the first disease-modifying therapy for AD.
Conclusions:
- Aducanumab represents a potential breakthrough in Alzheimer's treatment.
- Despite controversy, aducanumab offers hope for patients with Alzheimer's disease.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
428
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
428
01:26Alzheimer's Disease: Overview
901
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
901
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:24Parkinson's Disease: Treatment
572
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
572